The management of patients awaiting liver transplantation

Nature Reviews Gastroenterology and Hepatology

Volumn 6, Issue 11, 2009, Pages 648-659

  Li, Ka Kit ^a   Neuberger, James ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALBUMIN; ALPHA2B INTERFERON; AMPICILLIN; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; COTRIMOXAZOLE; DOXORUBICIN; ERYTHROPOIETIN; FUROSEMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IODINATED POPPYSEED OIL; LACTULOSE; LAMIVUDINE; MIDODRINE; NADOLOL; NORFLOXACIN; NUCLEOTIDE DERIVATIVE; OCTREOTIDE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROPRANOLOL; RIBAVIRIN; RIFAXIMIN; SORAFENIB; SPIRONOLACTONE; TERLIPRESSIN; UNINDEXED DRUG;

ASCITES; BACTERIAL PERITONITIS; CANCER ADJUVANT THERAPY; CHEMOEMBOLIZATION; DISEASE COURSE; DRUG DOSE INCREASE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS C; HEPATORENAL SYNDROME; HOSPITAL ADMISSION; HUMAN; IMMUNIZATION; INFECTION; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER GRAFT; LIVER TRANSPLANTATION; MALNUTRITION; NEUTROPENIA; OUTCOME ASSESSMENT; PARACENTESIS; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SODIUM RESTRICTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TURCOT SYNDROME; VARICOSIS;

HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; PREOPERATIVE CARE; WAITING LISTS;

EID: 71049152821     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.163     Document Type: Review

References (127)

1. NHS. waiting time to transplant [online], http://www.uktransplant.org.uk/ukt/about_transplants/ waiting_time_to_transplant/waiting_time_to_transplant.jsp (2009).
2. US Department of Health and Human Services. OPTN/SrTr Annual report. Welcome to the 2007 OPTN/SRTR Annual Report: Transplant Data 1997-2006, The US Organ. Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients [online], http://www.ustransplant.org/annual_reports/current/ (2007).
3. Cardenas, A. & Ginès, P. Management of complications of cirrhosis in patients awaiting liver transplantation. J. Hepatol. 42, S124-S133 (2005).
4. Runyon, B. A. & AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: An update. Hepatology 49, 2087-2107 (2009).
5. Garcia-Tsao, G., Sanyal, A. J., Grace, N. D. & Carey, W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 46, 922-938 (2007).
6. McCormick, P. A. Pathophysiology and prognosis of oesophageal varices. Scand. J. Gastroenterol. 207, 1-5 (1994).
7. D'Amico, G., Pagliaro, L. & Bosch, J. The treatment of portal hypertension: A metaanalytic review. Hepatology 22, 332-354 (1995).
8. de Franchis, R. Evolving consensus in portal hypertension: Report of the Baveno IV Consensus workshop on methodology of diagnosis and therapy in portal hypertension. J. Hepatol. 43, 167-176 (1995).
9. D'Amico, G., Pagliaro, L. & Bosch, J. Pharmacological treatment of portal hypertension: An evidence-based approach. Semin. Liver Dis. 19, 475-505 (1999).
10. Garcia-Pagan, J. C. & Bosch, J. Endoscopic band ligation in the treatment of portal hypertension. Nat. Clin. Pract. Gastroenterol. Hepatol. 2, 526-535 (2005).
11. de Franchis, R. Updating consensus in portal hypertension: Report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension. J. Hepatol. 33 846-852 (2000).
12. Grace, N. D. et al. Portal hypertension and variceal bleeding: An AASLD single topic symposium. Hepatology 28, 868-880 (1998).
13. Thalheimer, U., Triantos, C. K., Samonakis, D. N., Patch, D. & Burroughs, A. K. infection, coagulation, and variceal bleeding in cirrhosis. Gut 54, 556-563 (2005).
14. Soares-Weiser, K., Brezis, M., Tur-Kaspa, R. & Leibovici, L. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding (Cochrane review). Cochrane Database of Systematic Reviews, issue 2. Art No.: CD002907. doi:10.1002/14651858.CD002907 (2002).
15. Castaneda, B. et al. Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats. Hepatology 33, 821-825 (2001).
16. Sanyal, A. J. et al. Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology 111, 138-146 (1996).
17. Tripathi, D., Therapondos, G., redhead, D. N., Madhavan, K. K. & Hayes, P. C. Transjugular intrahepatic portosystemic stent shunt and its effects on orthotopic liver transplantation. Eur. J. Gastroenterol. Hepatol. 14, 827-832 (2002).
18. Hutchins, R. R., Patch, D., Tibballs, J., Burroughs, A. & Davidson, B. R. Liver transplantation complicated by embedded transjugular intrahepatic portosystemic shunt: A new method for portal anastomosis - a surgical salvage procedure. Liver Transpl. 6, 237-238 (2000).
19. Guerrini, G. P. et al. Impact of TiPS preliver transplantation for the outcome post-transplantation. Am. J. Transplant. 9, 192-200 (2009).
20. García-Pagán, J. C. et al. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: A multicenter randomised controlled trial. Gut 58, 1144-1150 (2009).
21. Fernández-Esparrach, G. et al. A prognostic model for predicting survival in cirrhosis with ascites. J. Hepatol. 34 46-52 (2001).
22. Gines, P. et al. Randomized study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94, 1493-1502 (1998).
23. Saab, S., Nieto, J. M., Lewis, S. K. & runyon, B. A. TiPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database of Systematic Reviews issue 3. Art. no.: CD004889. doi:10.1002/14651858.CD004889.pub2 (2006).
24. Navasa, M., Fernandez, J. & rodes, J. Bacterial infections in liver cirrhosis. Ital. J. Gastroenterol. Hepatol. 31, 616-625 (1999).
25. Fernandez, J., Navasa, M. & Gomez, J. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 35, 140-148 (2002).
26. Cardenas, A. et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: Incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 34, 671-676 (2001).
27. Vaquero, J. et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 125, 755-764 (2003).
28. Wong, F. et al. Sepsis in cirrhosis: Report on the 7th meeting of the international Ascites Club. Gut 54, 718-725 (2005).
29. Garcia-Tsao, G. Bacterial infections in cirrhosis: Treatment and prophylaxis. J. Hepatol. 42, S85-S92 (2005).
30. Caruntu, F. A. & Benea, L. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, treatment. J. Gastrointest. Liver Dis. 15, 51-56 (2006).
31. van Erpecum, K. J. Ascites and spontaneous bacterial peritonitis in patients with liver cirrhosis. Scand. J. Gastroenterol. 243 (suppl.), 79-84 (2006).
32. Sort, P. et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N. Engl. J. Med. 341, 403-409 (1999).
33. Rimola, A. et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: A consensus document. international Ascites Club. J. Hepatol. 32, 142-153 (2000).
34. Runyon, B. A. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 91, 1343-1346 (1986).
35. Fernandez, J. et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 133, 818-824 (2007).
36. Dagher, L. & Moore, K. The hepatorenal syndrome. Gut 49, 729-737 (2001).
37. Nair, S., Verma, S. & Thuluvath, P. J. Pre-transplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 35, 1179-1185 (2002).
38. Schütte, K., Bornschein, J. & Malfertheiner, P. Hepatocellular carcinoma - epidemiological trends and risk factors. Dig. Dis. 27, 80-92 (2009).
39. Ryder, S. D. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. British Society of Gastroenterology. Gut 52, 1-8 (2003).
40. Mazzaferro, V. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 14, 693-699 (1996).
41. Mazzaferro, V. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol. 10, 35-43 (2009).
42. Yao, F. Y. et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 33, 1394-1403 (2001).
43. Yao, F. Y. et al. Liver transplantation for hepatocellular carcinoma: Validation of the UCSF expanded criteria based on preoperative imaging. Am. J. Transplant. 7, 2587-2596 (2007).
44. Llovet, J. M., Fuster, J. & Bruix, J. intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 30, 1434-1440 (1999).
45. Poon, R. T. et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: Implications for a strategy of salvage transplantation. Ann. Surg. 235, 373-382 (2002).
46. Llovet, J. M. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Lancet 359, 1734-1739 (2002).
47. Lo, C. M. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35, 1164-1171 (2002).
48. Graziadei, I. W. et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 9, 557-563 (2003).
49. Oldhafer, K. J. et al. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: Marked tumor necrosis, but no survival benefit? J. Hepatol. 29, 953-959 (1998).
50. Decaens, T. et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl. 11, 767-775 (2005).
51. Maddala, Y. K. et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: Outcome with chemoembolization. Liver Transpl. 10, 449-455 (2004).
52. Sergio, A. et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness. Am. J. Gastroenterol. 103, 914-921 (2008).
53. Shim, J. H. et al. Association between increment of serum vEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci. 99, 2037-2044 (2008).
54. Ravaioli, M. et al. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation 27, 1780-1786 (2004).
55. Alba, E. et al. Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation. AJR Am. J. Roentgenol. 190 1341-1348 (2008).
56. Lin, S. M., Lin, C. J., Lin, C. C., Hsu, C. W. & Chen, Y. C. radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤4 cm. Gastroenterology 127, 1714-1723 (2004).
57. Shiina, S. et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129, 122-130 (2005).
58. Lu, D. S. et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 41, 1130-1137 (2005).
59. Martin, A. P. et al. Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation - a clinical and histological examination. Clin. Transplant. 20, 695-705 (2006).
60. Porrett, P. M. et al. Lack of benefit of pretransplant local-regional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl. 12, 665-673 (2006).
61. Mazzaferro, V. et al. radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: A prospective study. Ann. Surg. 240, 900-909 (2004).
62. Curley, S. A. et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann. Surg. 239, 450-458 (2004).
63. Freeman, R. B., Edwards, E. B. & Harper, A. M. waiting list removal rates among patients with chronic and malignant liver diseases. Am. J. Transplant. 6, 1416-1421 (2006).
64. Aloia, T. A., Adam, R., Samuel, D., Azoulay, D. & Castaing, D. A decision analysis model identifies the interval of efficacy for transarterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma awaiting liver transplantation. J. Gastrointest. Surg. 11, 1328-1332 (2007).
65. Llovet, J. M. et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 50, 123-128 (2002).
66. Yao, F. Y. et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: Implications for the current organ allocation policy. Liver Transpl. 9, 684-692 (2003).
67. Majno, P. E. et al. influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann. Surg. 226, 688-701 (1997).
68. Millonig, G. et al. response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 13, 272-279 (2007).
69. Cheng, B. Q. et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: A randomized controlled trial. JAMA 9, 669-677 (2008).
70. Hoffmann, K. et al. Prospective, randomized, double-blind, multi-center, phase iii clinical study on transarterial chemoembolization (TACE) combined with sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [iSrCTN24081794]. BMC Cancer 8, 349 (2008).
71. Mühlberger, N. et al. HCv-related burden of disease in Europe: A systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 9, 34 (2009).
72. Berenguer, M. Natural history of recurrent hepatitis C. Liver Transpl. 8, S14-S18 (2002).
73. Samuel, D. et al. interferon-a2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 124, 642-650 (2003).
74. Shergill, A. K. et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing LT. Am. J. Transplant. 5, 118 (2005).
75. Poynard, T. et al. impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122, 1303-1313 (2002).
76. Shiffman, M. L. et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 26, 780-785 (1997).
77. Fried, M. & Hadziyannis, S. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin. Liver Dis. 24, 47-54 (2004).
78. Heathcote, E. J. et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 7, 1673-1680 (2000).
79. Hadziyannis, S. J. et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140 346-355 (2004).
80. Crippin, J. S., McCashland, T., Terrault, N., Sheiner, P. & Charlton, M. R. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 8, 350-355 (2002).
81. Thomas, R. M. et al. infection with chronic hepatitis C virus and liver transplantation: A role for interferon therapy before transplantation. Liver Transpl. 9, 905-915 (2003).
82. Everson, G. T. et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 42 255-262 (2005).
83. Tekin, F., Gunsar, F., Karasu, Z., Akarca, U. & Ersoz, G. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCv-related decompensated cirrhotics. Aliment. Pharmacol. Ther. 27, 1081-1085 (2008).
84. Forns, X. et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J. Hepatol. 39, 389-396 (2003).
85. Carrión, J. A. et al. Antiviral therapy increases the risk of bacterial infections in HCv-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J. Hepatol. 50, 719-728 (2009).
86. Annicchiarico, B. E. et al. Treatment of chronic hepatitis C virus infection with pegylated interferon and ribavirin in cirrhotic patients awaiting liver transplantation. Transplant. Proc. 40, 918-920 (2008).
87. Iacobellis, A. et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study. J. Hepatol. 46, 206-212 (2007).
88. Iacobellis, A. et al. Sustained virologic responses following standard antiviral therapy in decompensated HCv-infected cirrhotic patients. Aliment. Pharmacol. Ther. 30, 146-153 (2009).
89. Camci, C. et al. Liver transplantation for hepatitis B in the United States. Transplant. Proc. 37, 4350-4353 (2005).
90. Gane, E. J. et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 132, 931-937 (2007).
91. Kim, W. R. et al. Decline in the need for liver transplantation for end stage liver disease secondary to hepatitis B in the US [abstract]. Hepatology 46, 238A (2007).
92. McCullough, A. J. & Bugianesi, E. Protein-calorie malnutrition and the etiology of cirrhosis. Am. J. Gastroenterol. 92, 734-738 (1997).
93. Figueiredo, F. et al. Impact of nutritional status on outcomes after liver transplantation. Transplantation 70, 1347-1352 (2000).
94. Selberg, O. et al. Identification of high- and low-risk patients before liver transplantation: A prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology 25, 652-657 (1997).
95. Hasse, J. M. Nutritional implications of liver transplantation. Henry Ford Hosp. Med. J. 38, 235-240 (1990).
96. Alvares-da-Silva, M. R. & Reverbel da Silveira, T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. Nutrition 21, 113-117 (2005).
97. Alberino, F. et al. Nutrition and survival in patients with liver cirrhosis. Nutrition 17, 445-450 (2001).
98. Sanchez, A. J. & Aranda-Michel, J. Nutrition for the liver transplant patient. Liver Transpl. 12, 1310-1316 (2006).
99. Plauth, M. et al. ESPEN guidelines on enteral nutrition: Liver disease. Clin. Nutr. 25, 285-294 (2006).
100. Campos, A. C., Matias, J. E. & Coelho, J. C. Nutritional aspects of liver transplantation. Curr. Opin. Clin. Nutr. Metab. Care 5 297-307 (2002).
101. Cordoba, J. et al. Normal protein diet for episodic hepatic encephalopathy: Results of a randomized study. J. Hepatol. 41 38-43 (2004).
102. Hirsch, S. et al. Controlled trial on nutrition supplementation in outpatients with symptomatic alcoholic cirrhosis. J. Parenter. Enteral Nutr. 17, 119-124 (1993).
103. Kearns, P. J. et al. Accelerated improvement of alcoholic liver disease with enteral nutrition. Gastroenterology 102, 200-205 (1992).
104. Cabré, E. et al. Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics: A randomized controlled trial. Gastroenterology 98, 715-720 (1990).
105. Le Cornu, K. A., McKiernan, F. J., Kapadia, S. A. & Neuberger, J. M. A prospective randomized study of preoperative nutritional supplementation in patients awaiting elective orthotopic liver transplantation. Transplantation 69, 1364-1369 (2000).
106. Senkal, M. et al. Outcome and costeffectiveness of perioperative enteral immunonutrition in patients undergoing elective upper gastrointestinal tract surgery: A prospective randomized study. Arch. Surg. 134, 1309-1316 (1999).
107. Heyland, D. K. et al. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA 286, 944-953 (2001).
108. Braga, M. et al. Perioperative immunonutrition in patients undergoing cancer surgery. results of a randomized double-blind phase iii trial. Arch. Surg. 134, 428-433 (1999).
109. Tepaske, R. et al. Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac immunonutrition in liver transplantation 295 surgery: A randomised placebo-controlled trial. Lancet 358, 696-701 (2001).
110. Plank, L. D. et al. Pre- and postoperative immunonutrition in patients undergoing liver transplantation: A pilot study of safety and efficacy. Clin. Nutr. 24, 288-296 (2005).
111. Chin, S. E. et al. Nutritional support in children with end-stage liver disease: A randomized crossover trial of a branched-chain amino acid supplement. Am. J. Clin. Nutr. 56, 158-163 (1992).
112. Guidelines for vaccination of solid organ transplant candidates and recipients. Am. J. Transplant. 4, 160-163 (2004).
113. Arguedas, M. R., McGuire, B. M. & Fallon, M. B. implementation of vaccination in patients with cirrhosis. Dig. Dis. Sci. 47, 384-387 (2002).
114. Idilman, R. et al. impaired antibody response rates after high dose short interval hepatitis B virus vaccination of immunosuppressed individuals. Hepatogastroenterology 50, 217-221 (2003).
115. Sester, M., Gärtner, B. C., Girndt, M. & Sester, U. vaccination of the solid organ transplant recipient. Transplant. Rev. 22, 274-284 (2008).
116. Poland, G. A. & Jacobson, R. M. Prevention of hepatitis B with the hepatitis B vaccine. N. Engl. J. Med. 351, 2832-2838 (2004).
117. Carey, W., Pimentel, R., Westveer, M. K., vogt, D. & Broughan, T. Failure of hepatitis B immunization in liver transplant recipients: results of a prospective trial. Am. J. Gastroenterol. 85, 1590-1592 (1990).
118. Chalasani, N., Smallwood, G., Halcomb, J., Fried, M. W. & Boyer, T. D. is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transpl. Surg. 4, 128-132 (1998).
119. Bonazzi, P. R. et al. Double-dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list. Braz. J. Infect. Dis. 12, 306-309 (2008).
120. Macedo, G., Maia, J. C., Gomes, A., Teixeira, A. & ribeiro, T. Efficacy of a reinforced protocol of HBv vaccination in cirrhotic patients waiting for orthotopic liver transplantation. Transplant. Proc. 32, 2641 (2000).
121. Pascasio, J. M. et al. response to a vaccination schedule with 4 doses of 40 μg against hepatitis B virus in cirrhotic patients evaluated for liver transplantation. Transplant. Proc. 40, 2943-2945 (2008).
122. Domínguez, M., Bárcena, R., García, M., López-Sanroman, A. & Nuño, J. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl. 6, 440-442 (2000).
123. Stark, K. et al. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J. Infect. Dis. 180 2014 (1999).
124. Arslan, M., wiesner, R. H., Poterucha, J. J. & Zein, N. N. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 72, 272-276 (2001).
125. Kumar, D. et al. A randomized, double-blind, placebo-controlled trial to evaluate the primeboost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin. Infect. Dis. 47, 885-892 (2008).
126. Gaeta, G. B. et al. Influenza vaccination in patients with cirrhosis and in liver transplant recipients. Vaccine 27, 3373-3375 (2009).
127. Soesman, N. M. et al. Efficacy of influenza vaccination in adult liver transplant recipients. J. Med. Virol. 61, 85-93 (2000).